- Home
- LFVN vs LITS Comparison
LFVN vs LITS Comparison
Compare LFVN & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFVN | LITS |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 41.5M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | LFVN | LITS |
|---|---|---|
| Price | $5.21 | $1.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 153.4K | ★ 227.9K |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | ★ 226.09 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $203,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.68 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $0.95 |
| 52 Week High | $15.00 | $3.03 |
Technical Indicators
Market Signals| Indicator | LFVN | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 46.72 |
| Support Level | $4.10 | $1.01 |
| Resistance Level | $5.37 | $1.16 |
| Average True Range (ATR) | 0.42 | 0.05 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 63.35 | 30.89 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.